Education
About Us
Working with TipRanks
Follow Us
IMV (GB:0V11)
LSE:0V11
0V11 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
IMV News
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
0V11 FAQ
What was IMV’s price range in the past 12 months?
Currently, no data Available
What is IMV’s market cap?
Currently, no data Available
When is IMV’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IMV’s earnings last quarter?
Currently, no data Available
Is IMV overvalued?
According to Wall Street analysts IMV’s price is currently Undervalued.
Does IMV pay dividends?
IMV does not currently pay dividends.
What is IMV’s EPS estimate?
IMV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IMV have?
Currently, no data Available
What happened to IMV’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IMV?
Currently, no hedge funds are holding shares in GB:0V11
Company Description
IMV
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
0V11 Stock 12 Month Forecast
Average Price Target
―IMV
―
ESSA Pharma
―
Gritstone bio
―
Karyopharm Therapeutics
―
Diamedica Therapeutics
―